The effect of intravesical chemohyperthermia with mitomycin in non-muscle-invasive bladder tumour patients who cannot tolerate BCG treatment or recur after treatment and refuse cystectomy-Reference-Cited by-同舟云学术

The effect of intravesical chemohyperthermia with mitomycin in non-muscle-invasive bladder tumour patients who cannot tolerate BCG treatment or recur after treatment and refuse cystectomy

Published:2024-07-31 Issue: Volume: Page:
ISSN:1573-2584
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Akdaş Enes Malik^ORCID,Çulha Mustafa Melih^ORCID,Telli Engin^ORCID,Bosnalı Efe^ORCID,Baykal Serdar^ORCID,Baynal Enes Abdullah^ORCID,Teke Kerem^ORCID,Kara Önder^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11255-024-04169-4.pdf

Reference26 articles.

1. Nativ O, Witjes JA, Hendricksen K et al (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 182(4):1313–1317

2. Nadler RB, Catalona WJ, M’liss AH et al (1994) Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 152(2):367–373

3. Zhao H, Chan VW, Castellani D et al (2021) Intravesical chemohyperthermia vs. bacillus Calmette-Guerin Instillation for intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis. Front Surg. 8:775527

4. Di Stasi SM, Giannantoni A, Giurioli A et al (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7(1):43–51

5. Tan WS, Prendergast A, Ackerman C et al (2023) Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label. Random Control Trial Eur Urol 83(6):497–504